Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crisugabalin vs sedating antihistamine added to second-generation antihistamines for chronic pruritus
ChiCTR2600122784Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of crisugabalin besilate in prurigo nodularis (PN) and chronic idiopathic pruritus (2 arms), sponsored by Southern Medical University Dermatology Hospital. Primary endpoint: Change in Worst Itch Numeric Rating Scale (WI-NRS) weekly average from baseline at Week 4. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
crisugabalin besilate
03
Conditions
prurigo nodularis (PN)chronic idiopathic pruritus
Beyond the preview
Go deeper on ChiCTR2600122784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122784.